checkAd

     112  0 Kommentare Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference - Seite 3

    Ocugen Contact: 
    Ken Inchausti
    Head, Investor Relations & Communications
    IR@Ocugen.com


    Lesen Sie auch


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von globenewswire
    Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference - Seite 3 MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer